Mercosur bloc moves to tighten blood products quality and safety
This article was originally published in Clinica
South America’s Mercosur trading bloc has been discussing technical and regulatory issues related to blood products. Brazil’s foreign affairs ministry and healthcare products regulatory agency Anvisa hosted a week of workshops in Campinas, São Paulo. The information-sharing event, which ended yesterday, was attended by teams of representatives from Argentina, Brazil, Paraguay, Uruguay and Venezuela. Its main aim was to “promote improvements in quality- and safety-assurance in this area, through tighter regulation”, according to Anvisa. The main subjects on the agenda were good manufacturing practice (GMP), national regulatory frameworks and the harmonisation of regulations across the bloc.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.